Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of Nektar's technology platforms to potential new drug candidates is therefore very uncertain and unpredictable and one or more research and development programs could fail; (iv) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (v) the outcome of any future intellectual property or other litigation related to Nektar's proprietary product candidates or complex commercial agreements; (vi) if Nektar is unable to establish and maintain collaboration partnerships on attractive commercial terms (such as for NKTR-102), our business, results of operations and financial condition could suffer; and (vii) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended June 30, 2010 filed with the SEC on July 28, 2010, the Current Report on Form 8-K filed with the SEC today, and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 to be filed with the SEC on or about November 4, 2010.  Actual results could differ materially from the forward-looking statements contained in this press release.  Nektar undertakes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise.

Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics(650) 631-4954Susan Noonan/SA Noonan Communications, LLC(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners(650) 575-1509 Michelle Corral/BCC Partners(415) 794-866
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014 /PRNewswire/ ... the industry leader in bioactive lipid-targeted therapeutics, received official ... company has been granted another key patent supporting ... This newly issued patent, European patent No. 2087002, ... drug substance in Lpath,s two lead compounds, iSONEP ...
(Date:10/20/2014)... , Oct. 20, 2014   Mary,s Medicinals ... for Caring, is a 4-Star Sponsor of Operation ... Veterans with unique products, programs and services to assist ... freedom. Key Facts: , An ... is a safe and effective treatment for pain, Post-traumatic ...
(Date:10/20/2014)... 20, 2014  BioPontis Alliance for Rare Disease ... announced today the creation of a joint venture ... the rare disease known as Charcot- Marie-Tooth (CMT) ... model earlier this month. Today,s partnership announcement with ... model where researchers and all CMT dedicated organizations ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... 3 Despite the pop in the shares of Dendreon ... been approved by the FDA, the biotech sector failed to build ... month with the Burrill Biotech Select Index dropping 2 percent in ... including Amgen and Gilead Sciences cut their profit forecasts citing the ...
... , , ... Bowel Control and Prevent Clinical Complications for People With,Stomas. , , ... GI, located in the Misgav Venture Accelerator, has reported,encouraging interim results in its animal trials of the ... , , ...
Cached Medicine Technology:Biotech Posts Weak Performance in April 2Biotech Posts Weak Performance in April 3Biotech Posts Weak Performance in April 4Stimatix GI Reports Encouraging Interim Results 2
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
(Date:10/19/2014)... 19, 2014 Dr. Babatunde Osotimehin, Executive ... news of a ceasefire agreement that is expected to ... girls who were kidnapped from the north-eastern Nigerian town ... captivity long enough, and it is high time they ... Dr. Osotimehin. , "We owe it to these girls ...
(Date:10/19/2014)... October 20, 2014 Recently, Top10BestSEOHosting.com ... announced that JustHost, GoDaddy and HostMonster are the ... VPS (Virtual Private Server) is the method of ... each of which has the appearance and capabilities ... is why the site pays close attention to ...
(Date:10/19/2014)... October 19, 2014 Visual Impact ... has just been released to the public generating ... body building and fitness community. The commotion surrounding ... DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. , ... hitting what is commonly known as a training ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... , NEW YORK (March 16, 2011) -- On March ... the 2nd World Congress on Interventional Therapies for Type ... surgery as a treatment option. The three-day meeting, hosted ... City, will bring together physicians, scientists and policymakers representing ...
... organized follow-up care for depression effectively and efficiently, according ... patients that the Journal of General Internal Medicine ... five months, compared to the half of the patients ... had three online care management contacts with a trained ...
... News) -- Newly proposed national standards for mercury, arsenic ... prevent as many as 17,000 premature deaths and 11,000 ... Protection Agency. The proposed standards, released Wednesday by ... also prevent 120,000 cases of childhood asthma symptoms and ...
... This release is available in French . ... projects on regenerative medicine and nanomedicine received $16 million in ... Research (CIHR) and the Canadian Space Agency (CSA), were announced ... Member of Parliament for Oshawa; Dr. Jane Aubin, Scientific Director ...
... By Maureen Salamon HealthDay Reporter , ... be wise to avoid chatting on cell phones while ... more risky for that age group than for college ... Illinois, 18 older adults aged 59 to 81 and ...
... -- Children and adolescents growing up with inflammatory bowel disease ... by researchers at McMaster University and the McMaster Children,s Hospital. ... online, shows children and youth with the most common ... per cent lower than other children their age, and their ...
Cached Medicine News:Health News:Diabetes Surgery 2nd World Congress 2Health News:Diabetes Surgery 2nd World Congress 3Health News:Diabetes Surgery 2nd World Congress 4Health News:Diabetes Surgery 2nd World Congress 5Health News:Online messaging delivers follow-up care for depression 2Health News:EPA Proposes Tougher Air Pollution Rules for Power Plants 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 2Health News:Important funding for nanomedicine research to improve diagnosis and treatment 3Health News:Crossing Street While on Cell Phone Risky for Seniors 2Health News:Youth with IBD are less fit than their peers: McMaster study 2
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
Medicine Products: